# ENDRA LIFE SCIENCES INC. (NDRA) · Edgar & Edgarette company card

> Endra Life Sciences (NDRA) reported revenue of $0 million in FY2020, operating margin null against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 81.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1681682 · fiscal year ended 2020-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NDRA) · [JSON](https://www.pops4.com/boards/company/NDRA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$11M |
| Capital spending | $75,333 |
| Free cash flow | −$11M |
| Cash | $7M |
| Long-term debt | — |
| Total assets | $9M |
| Total equity | $7M |
| Equity ÷ assets | 81.8% |
| Return on equity | -163.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -20.02 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative (-$5.2M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2020). Experience: one year on record; operating margin null, up from null. Soundness: equity 81.8% of assets, return on equity -163.6%. Credibility: four or more audited years, reasonable weight. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin null against a 7.5% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-04-21 ([filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026045885/0001213900-26-045885-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2026-03-25 ([filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/0001213900-26-033878-index.htm))
- Item 5.02 Director or officer change: 2, latest 2025-12-15 ([filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390025121374/0001213900-25-121374-index.htm))

## Recent filings

- 8-K · filed 2026-10-01 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026105899/0001213900-26-105899-index.htm)
- 8-K · filed 2026-08-17 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090747/0001213900-26-090747-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026090027/0001213900-26-090027-index.htm)
- 8-K · filed 2026-07-09 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026076526/0001213900-26-076526-index.htm)
- 8-K · filed 2026-06-26 · 1.01 Entry into a Material Definitive Agreement; 5.01 Changes in Control of Registrant; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026072268/0001213900-26-072268-index.htm)
- 8-K · filed 2026-06-25 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/0001213900-26-071804-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001681682.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1681682

## Cite

POPS4, Edgar & Edgarette: ENDRA LIFE SCIENCES INC. (NDRA) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/NDRA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2020, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

